December 12, 2018

Opening the door to personalized medicine

Lausanne/Neuchâtel, 10 December 2018—SUN bioscience launches its Gri3D™ platform. Industrialized with CSEM technological support, Gri3D™ enables the large-scale, standardized, rapid, and reliable production of 3-D in vitro organoid cultures from patient stem cells. This groundbreaking, large scale standardizing of organoids represents a key advancement toward truly personalizing medicine.

Nathalie Brandenberg (SB), Sarah Heub (CSEM), Sylke Hoehnel (SB), and Gilles Weder (CSEM)
Press release (PDF)

Related Press

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

Deux prototypes d'Active Aligner équipés de diffuseurs antibactériens. Le prototype de droite contient un liquide bleu mettant en évidence l'innovation : un système de microcanaux imprimé en 3D. Celui de gauche représente le prototype d'aligneur transparent dans son apparence finale.

19 September 2024

Dental innovation: Actival and CSEM launch 3D antibacterial aligners

Actival is redefining dental alignment with its innovative 'Active Aligners.' They feature patented 3D-printed microchannel technology developed by CSEM....

Hand holding an implantable biosensor, the size of a match, approx. 1 cm long

25 July 2024

CSEM develops a pioneering implant to support reproductive medicine

Swiss-based start-ups Impli and Yalosys, and the technology innovation center CSEM present an implantable biosensor for real-time fertility hormone monitoring....